All 22 patients in the $ONCS combo trial had a very low of <22 TIL. They are all nonresponders based on $ONCS diagnosis. Of the 22 patients, 9 had been previously treated with, in "OTHER TRIALS" , checkpoint inhibitors therapy with obvious zero response.
That is good news. Looking back over the data release it does appear that they were implying that the 9 patients were previous pd-1 failures and that 3 of the 9 went on to have a response with combo therapy. That is what we needed to hear. This is probably why the share price went down today because 33% is lower than the 48% CR for the current trial. The market is maybe predicting that the registration trial will produce a lower overall response rate of 33% based on this small subset of 9 patients. If that is the case and the registration trial produces a 33% CR than that is still good enough to get us to market where there is no real alternative presently for pd-1 monotherapy failures.
News 
Market Data 
Discover 
